Maintenance of naive and Th1 CD4 phenotype and lack of CD8 activation in patients switching from protease inhibitors to nonnucleoside reverse transcriptase inhibitor-based antiretroviral regimens

J Acquir Immune Defic Syndr. 2001 Dec 1;28(4):401-3. doi: 10.1097/00126334-200112010-00017.
No abstract available

Publication types

  • Comparative Study
  • Letter
  • Research Support, Non-U.S. Gov't

MeSH terms

  • ADP-ribosyl Cyclase
  • ADP-ribosyl Cyclase 1
  • Anti-HIV Agents / therapeutic use*
  • Antigens, CD*
  • Antigens, Differentiation / analysis
  • Antiretroviral Therapy, Highly Active
  • CD4-Positive T-Lymphocytes
  • CD8-Positive T-Lymphocytes
  • E-Selectin / analysis
  • HIV Infections / drug therapy*
  • HIV Infections / immunology
  • HIV-1*
  • Humans
  • Leukocyte Common Antigens / analysis
  • Lymphocyte Activation
  • Membrane Glycoproteins
  • NAD+ Nucleosidase / analysis
  • RNA, Viral / analysis
  • Reverse Transcriptase Inhibitors / therapeutic use*

Substances

  • Anti-HIV Agents
  • Antigens, CD
  • Antigens, Differentiation
  • E-Selectin
  • Membrane Glycoproteins
  • RNA, Viral
  • Reverse Transcriptase Inhibitors
  • Leukocyte Common Antigens
  • ADP-ribosyl Cyclase
  • CD38 protein, human
  • NAD+ Nucleosidase
  • ADP-ribosyl Cyclase 1